We develop colon-targeted LNPs through pH-gated lipid design, colonic ligand functionalization, and oral-compatible formulation, covering everything from lipid synthesis and ligand conjugation to gastrointestinal stability testing and in vivo colonic delivery evaluation.
Colon-targeted LNPs are designed to carry nucleic acids, proteins, or small molecules through the stomach and small intestine and release them at the colonic mucosa. A conventional LNP optimized for intravenous use does not survive this journey: gastric acid changes its ionization state, bile salts strip lipids from the particle, digestive enzymes attack the lipid matrix, and the mucus layer blocks access to epithelial cells. Colon-targeted systems therefore combine three design layers — a lipid composition that resists the gastrointestinal environment, a release mechanism triggered by colonic pH or microbial enzymes, and a surface ligand that favors uptake by epithelial cells, macrophages, or gut-homing leukocytes.
BOC Sciences provides integrated targeted LNP development, covering ionizable lipid screening, colonic ligand synthesis, surface functionalization, payload encapsulation, oral dosage-form integration, and cellular and in vivo evaluation. We support mRNA, siRNA, miRNA, plasmid DNA, genome-editing, protein, and small-molecule payloads, with formulation strategies selected according to the target colonic cell population and the intended administration route.
Colon-Targeted Lipid Nanoparticle IllustrationOur services connect lipid chemistry, gastrointestinal barrier engineering, nanoparticle formulation, and biological evaluation in one development plan. A project can start from an existing LNP formulation, a candidate ligand, an enteric coating concept, or nothing more than a target cell population and a payload. We define the development scope according to where in the colon the payload should act and how the formulation will be administered.
We examine how ionizable lipid structure and supporting lipids influence particle integrity in gastric and intestinal fluids, and how they affect uptake once the particle reaches the colonic mucosa.
We build the targeting layer around the cell population that actually needs the payload — absorptive epithelium, goblet cells, resident macrophages, or gut-homing leukocytes — because each requires a different recognition chemistry.
An orally delivered LNP is only as good as the dosage form that carries it. We treat encapsulation, protective coating, and reconstitution behavior as one connected problem.
We test the formulation in the sequence it will actually experience: stomach, small intestine, mucus layer, target cell, and tissue. Each step has its own readout, so a failure can be attributed to a specific barrier.
Colon targeting can be achieved by protecting the particle until it reaches the colon, by directing it to a specific colonic cell type, or by combining both. BOC Sciences supports lipid design, ligand synthesis, coating integration, formulation, and delivery evaluation across all four strategies below, so that the choice is driven by the payload and the target cell rather than by a fixed platform.
pH-responsive LNPs keep the particle intact while gastric pH is low and release it once the environment becomes neutral to slightly alkaline in the distal intestine and colon. This is the most direct route to colonic exposure for oral dosing, and it is compatible with both liquid and solid dosage forms.
Research basis: Reviews of colon-targeted oral delivery describe pH-gated coatings and capsules that protect nucleic acid carriers through gastric transit and release them in the colonic lumen (Journal of Controlled Release, 2023). Enzyme-cleavable linkers that respond to colonic microbiota provide a complementary trigger.
Ligand-functionalized LNPs add a recognition layer on top of tissue-level accumulation. In inflamed colon tissue, several receptors are consistently upregulated on activated macrophages, damaged epithelial cells, and gut-homing leukocytes, which makes receptor-mediated uptake a practical design target.
Research basis: LNPs displaying the integrin-binding domains of a gut endothelial ligand targeted the high-affinity conformation of α4β7 integrin, silenced interferon-γ in the gut, and improved outcomes in experimental colitis without liver toxicity (Nature Nanotechnology, 2021).
Some edible-plant lipid vesicles accumulate in the colon after oral administration, and their lipid profile can be reconstructed with defined components. This biomimetic route offers an alternative to polymer coatings for payloads that are sensitive to coating stress.
Research basis: Orally administered LNPs reconstituted from three ginger-derived lipids at a 5:2:3 ratio formed ~200 nm particles, raised IL-22 expression in colonic mucosa, and accelerated healing in a mouse colitis model (Biomaterials, 2022).
Mucus is the last barrier before the epithelium. Whether a particle should adhere to it or pass through it depends on the target: sustained residence favors local immune modulation, while rapid penetration favors epithelial uptake and transepithelial transport.
Research basis: Studies of oral nanocarriers consistently show that intermediate PEG surface density and near-neutral charge improve mucus transit, whereas strongly cationic surfaces are retained in the mucus layer.(Journal of Nanobiotechnology, 2022)
Tell us your payload, target colonic cell population, and dosing route. BOC Sciences can compare feasible strategies, synthesize the required lipids and ligands, and build a side-by-side evaluation plan.
Colon delivery is not equally difficult for every payload. Nucleic acids need protection from nucleases in the gut lumen, proteins need mild loading conditions, and small molecules need retention during coating and drying. We match the loading route and the GI-protection architecture to the payload class.
| Payload Type | Supported Uses & Colon-Targeted LNP Development Considerations | Request Information |
|---|---|---|
| Colon-Targeted LNP for mRNA | Used for local expression of cytokines, tight-junction proteins, or reporter genes in colonic epithelium and macrophages. Development focuses on mRNA integrity after gastric exposure, encapsulation stability in bile-salt media, and expression restricted to the intestinal tract. Supported by our lipid nanoparticles for mRNA delivery platform. | Inquiry |
| Colon-Targeted LNP for siRNA | Applied to knockdown of pro-inflammatory mediators such as TNF-α, CD98, or MAP4K4 in colonic macrophages and epithelium. Key readouts are silencing in colonic tissue versus liver and spleen, payload retention during coating, and release at colonic pH, drawing on our lipid nanoparticles for siRNA delivery experience. | Inquiry |
| Colon-Targeted LNP for miRNA | Suited to pathway-level regulation in intestinal inflammation and fibrosis, where a single miRNA can affect several mediators at once. Development considers duplex stability, loading ratio, and whether the mimic or inhibitor format changes the preferred lipid composition, supported by lipid nanoparticles for miRNA delivery. | Inquiry |
| Colon-Targeted LNP for Cas9 mRNA and sgRNA | Designed for local genome-editing research in colonic epithelium or immune cells, for example editing a cytokine gene in activated macrophages. Work covers co-loading of Cas9 mRNA and guide RNA, editing readouts in colonic cell models, and particle consistency across the coating step, using our lipid nanoparticles for CRISPR RNP delivery capabilities. | Inquiry |
| Colon-Targeted LNP for pDNA | Used where a larger, more durable genetic unit is required, including reporter constructs and secretion cassettes. Development emphasizes condensation with cationic components, protection from shear during coating, and nuclear delivery in epithelial models, supported by lipid nanoparticles for pDNA delivery. | Inquiry |
| Colon-Targeted LNP for Small Molecule | Relevant to poorly soluble anti-inflammatory and cytotoxic compounds that benefit from local exposure with reduced systemic burden. Formulation work covers drug–lipid compatibility, loading method, retention during enteric coating, and release profiling, supported by lipid nanoparticles for small molecule delivery. | Inquiry |
| Colon-Targeted LNP for Protein and Peptide | Applied to enzymes, cytokines, and peptide regulators intended for local intestinal activity. Development uses mild loading conditions, aggregation control, and activity assays after GI exposure, drawing on our protein encapsulation in LNPs experience. | Inquiry |
| Colon-Targeted LNP for Fluorescent and Tracking Labels | Supports mapping of where particles go after oral dosing: gastric survival, small-intestinal loss, mucus retention, and colonic tissue accumulation. Labeled formulations are prepared so that the label does not alter surface properties, and imaging data are paired with quantitative tissue measurements. | Inquiry |
| Colon-Targeted LNP for Custom Payload | For co-delivery systems, unusual cargo, or early feasibility work. We evaluate payload compatibility, loading sequence, targeting modification route, coating tolerance, and performance in the agreed colonic models before committing to a formulation line. | Inquiry |
Share your payload type, target cell population, and dosing route, and BOC Sciences will propose a loading and protection strategy that fits your project.
Projects begin with a target cell population and a route, not with a fixed formulation. We organize the work into four stages and revise the plan as gastrointestinal and biological data accumulate.

We review the payload class, the intended colonic cell type — absorptive epithelium, goblet cells, macrophages, or gut-homing leukocytes — the administration route, and the biological readout that will define success. Route selection is treated as a design variable in its own right, as summarized in this guide to lipid nanoparticle administration route selection, because oral, rectal, and intravenous delivery impose different barriers on the same particle.

We propose candidate ionizable lipids, helper lipid and cholesterol balances, and a protection concept — enteric coating, pH-responsive shell, galactolipid composition, or microparticle embedment. Molar ratios are optimized through structured LNP lipid ratio optimization services, and every targeted design is paired with a matched non-targeted control so that the ligand contribution can be measured rather than assumed.

Candidates are prepared under controlled mixing, coated or encapsulated, and then tested in sequence: buffer, simulated gastric fluid, simulated intestinal fluid, and bile-salt medium. During LNP process optimization, we adjust lipid concentration, flow-rate ratio, coating thickness, purification, and buffer exchange, and advance only candidates that hold size, PDI, and payload retention within agreed limits at every stage.

Selected candidates are tested in colonic epithelial and macrophage models using uptake imaging, flow cytometry, and payload-specific endpoints such as reporter expression, target knockdown, or editing frequency, supported by nanoparticle cellular uptake testing. In vivo work then compares colonic tissue exposure against small-intestinal, hepatic, and splenic distribution, and findings are delivered as a comparative dataset with documented tradeoffs and recommended next experiments.
A colon-targeted LNP can look perfect in buffer and still deliver nothing to the colon. We separate the gastrointestinal, mucus, release, and cellular failure modes and test each one, so that the next iteration targets the step that is actually limiting performance.
✔ Gastric Acid, Enzymatic, and Bile-Salt Instability
Low pH alters the ionization state of the lipid, bile salts extract lipid from the particle, and lipases attack the lipid matrix. We test each condition separately rather than pooling them into one "GI stability" number, then adjust saturation, cholesterol content, and coating thickness accordingly. When instability dominates, lipid nanoparticle stability profiling under biorelevant media identifies which component is being lost.
✔ Mucus Entrapment and Limited Epithelial Access
A particle that adheres too strongly never reaches the epithelium, while one that repels mucus too completely may be cleared before it can be taken up. We measure mucus diffusion and epithelial uptake for the same batch, then tune surface charge and PEG density to reach the balance the target requires, using labeled particles to confirm where the population actually ends up.
✔ Premature Small-Intestinal Release or Hepatic Diversion
Releasing the payload too early wastes the dose before the colon, while intravenous routes tend to concentrate particles in the liver. We profile release across the pH range from stomach to colon through nanoparticle drug release profiling, and compare colonic release with hepatic accumulation so that the trigger condition can be moved rather than guessed.
✔ Poor Cell-Type Selectivity and Endosomal Retention
Uptake by the wrong cell type, or uptake without cytosolic release, both read as "no effect." We compare ligand density and receptor expression across the relevant colonic cell populations, and pair uptake data with LNP endosomal escape evaluation so that a post-uptake block is identified before the formulation is redesigned.
Send us your lipid composition, coating concept, payload, and the results you already have. BOC Sciences can isolate the limiting barrier and propose a focused comparison study.
Colon-targeted LNPs are used wherever local intestinal exposure matters more than systemic circulation: inflammatory bowel disease, colorectal cancer, intestinal fibrosis, and mucosal immune modulation. BOC Sciences supports formulation and evaluation work across these areas, from payload selection to colonic distribution studies.
Tell us your intended application and the barrier you have already run into. BOC Sciences can design, synthesize, formulate, and evaluate colon-targeted LNPs around your project rather than around a fixed catalogue.
Ionizable lipids, PEG-lipid anchors, galactolipid components, and targeting ligands are sourced through our own material routes rather than assembled from unrelated suppliers, so formulation and material supply move on the same timeline and stay consistent between batches.

Each project has a named technical contact who reviews the data with you directly. Feasibility feedback comes back quickly, and formulation adjustments are discussed against your readouts rather than delivered as a report after the fact.
When a published structure does not fit your target cell or route, we design and synthesize the ionizable lipid, linker, or ligand that does. This keeps the chemistry responsive to the biology instead of forcing a project onto an existing catalogue item.
Work can be scoped as a single stage — lipid synthesis, ligand conjugation, encapsulation, coating, GI stability testing, or in vivo distribution — or as a full program. Teams with existing capabilities can fill only the gap they have, and expand the scope when results justify it.
Simulated gastric and intestinal exposure, mucus and epithelial uptake, macrophage delivery, endosomal escape assessment, and in vivo colonic distribution are run within one platform, so results are directly comparable across candidates and across iterations.
Oral colon-targeted LNPs must withstand gastric acid (pH 1–2.5), bile salts, pancreatic lipase, and the overlying mucus barrier before reaching the colonic lumen. Protection is typically engineered on two levels: a pH-responsive enteric shell that stays intact below pH ~6 and dissolves only in the terminal ileum and colon, and an intrinsically robust lipid core, achieved through bile-salt-tolerant ionizable lipids and cholesterol-rich helper lipid ratios that slow enzymatic erosion. At BOC Sciences, every candidate formulation is challenged in simulated gastric and fasted-state intestinal biorelevant media, with size, encapsulation retention, and release-onset endpoints quantified before any in vivo work is initiated.
Inflamed colonic tissue overexpresses several addressable markers, each mappable to a ligand class: CD44 on activated epithelial and cancer cells, targeted with hyaluronic acid coatings; folate receptor-α on activated macrophages, captured by folate-conjugated PEG anchors; mannose receptors on macrophages and dendritic cells; MAdCAM-1 on gut-homing vasculature, recognized by conformation-sensitive ligands binding high-affinity α4β7 integrin; and Ly6C on inflammatory monocytes. The optimal ligand depends on the disease model and target cell population. BOC Sciences maintains a ligand panel covering these targets and runs comparative uptake screening in Caco-2, HT-29, HCT116, and macrophage models to identify the best-matching surface chemistry for each project.
Yes. The main obstacles are gastric destruction, dilution along the small intestine, and competitive hepatic uptake after intestinal absorption. Effective oral siRNA-LNP designs typically combine a pH-responsive or biomimetic lipid shell for GI protection, a particle size window of roughly 100–200 nm for mucus diffusion, and macrophage-directed surface chemistry such as mannose ligands or galactolipid-rich biomimetic membranes. In one BOC Sciences project, an oral TNF-α siRNA formulation screened across twelve ionizable lipids and four GI-protection architectures achieved approximately four-fold higher colonic siRNA exposure than the parenteral-reference composition in a DSS colitis model, with TNF-α expression in colonic tissue correspondingly suppressed.
Colon-targeted LNPs accommodate a broad payload range: siRNA and miRNA for gene silencing in epithelial or immune cells; mRNA encoding IL-10 or IL-22 for local immunomodulation; Cas9 mRNA with sgRNA or pre-formed ribonucleoprotein complexes for genome editing; plasmid DNA; hydrophobic small molecules such as 5-aminosalicylic-acid derivatives or kinase inhibitors; peptides and proteins protected from proteolysis; and fluorescent or radiolabeled tracers for biodistribution mapping. Lipid charge ratio, buffer system, and loading chemistry are tuned per payload class, and co-encapsulation of a nucleic acid together with a small molecule within a single particle is also achievable through matched ionizable lipid selection.
Evaluation proceeds across three levels. First, biorelevant GI stability: sequential incubation in simulated gastric fluid (pH ~1.2) and bile-salt-containing intestinal medium, tracking particle size, encapsulation retention, and release onset. Second, cellular assays: uptake, knockdown, and expression readouts in Caco-2, HT-29, HCT116, and Raw 264.7 macrophage models, complemented by endosomal escape assessment. Third, in vivo distribution: fluorescently labeled LNPs administered in DSS- or TNBS-induced colitis models, with colonic accumulation quantified against liver and small intestine by imaging and tissue analysis. BOC Sciences provides this entire evaluation chain as one integrated package, so all data sets are generated under directly comparable conditions.